PharLyfe+
Medicated Oral Film Solution
Customer Problem
Patients, particularly children, and elderly patients, often face significant challenges in taking medication due to difficulty in swallowing pills or invasive injection procedures.
This often makes giving medication stressful and inefficient, leading to spills, missed doses, or patients refusing to take the medicine.
Many healthcare facilities lack non-invasive, accurate, and easy-to-administer drug delivery alternatives, particularly for diverse patient groups such as pediatrics and palliative care.
How the Company Solves the Problem
PharLyfe+ provides thin, flexible, lightweight oral films that can be easily attached inside the cheek, delivering medication accurately and quickly
The films eliminate the need for water, injections, or large pills, making them ideal for patients who have difficulty swallowing.
They address the challenges of accurate dose delivery with proprietary technology, overcoming limitations seen in older film-based solutions.
PharLyfe+ employs a dual sales approach to bring the film to market:
Premix Powder Sales: Providing premix powders to hospitals, enabling on-site production of medicated films without requiring regulatory approval.
Finished Medicated Film Sales: Distributing fully manufactured and regulatory-approved medicated films, leveraging strategic partnerships with pharmaceutical companies to scale production and distribution.
Traction and Key Metrics
Revenue Streams: Ongoing revenue from premix powder sales and training pharmacy staff for in-house film production.
Recent Developments: Two restructured hospitals have secured grants to initiate clinical trials using PharLyfe+ films across patient groups including palliative care, pediatrics, and surgical patients. These trials will generate valuable clinical data and substantiate the efficacy of PharLyfe+ solutions in real-world healthcare settings.
Market Opportunity
Total Addressable Market (TAM): $370 billion global alternative drug delivery systems market.
Serviceable Addressable Market (SAM): High demand within pediatric, geriatric, and specialized care (e.g., surgical, palliative) segments.
Growth Drivers:
Growing need for non-invasive, easy-to-administer drug delivery solutions.
Increasing focus on precision medicine and improving patient compliance.
Competitive Landscape
Key Competitors:
Traditional drug delivery methods (tablets, capsules, injections).
Limited competitors in the specialized oral film segment due to technological barriers in accurate dose delivery.
6. SWOT Analysis
Strengths:
Proven product-market fit with premix powders already generating revenue.
Validation through hospital-led clinical trials for expanded applications.
Proprietary technology ensuring precise dose delivery.
Current oral film technologies often fail to deliver accurate and consistent dosages, leading to inefficacy and regulatory hurdles.
Weaknesses:
Dependence on successful completion of clinical trials and regulatory approvals for finished films.
Scaling manufacturing capabilities requires significant capital and strong partnerships.
Opportunities:
Diversification of use cases into high-value patient groups like palliative care and surgical patients.
Expansion through pharmaceutical partnerships leveraging existing distribution networks.
Threats:
Delays in regulatory approvals or clinical trial outcomes could impact commercialization timelines.
Investment Considerations
Stage of Growth: Growth-stage startup with revenue from premix sales and active clinical trials to validate finished films.
Funding Needs: Requested $1 million for 20% equity to scale manufacturing, complete regulatory filings, and expand partnerships.
Exit Strategy:
Potential acquisition by pharmaceutical companies.
Opportunity for IPO upon achieving significant market penetration and scaling of operations.
General Company Information
Founders: Prof Sui Yung Chan and Tan, Poh Leng (CEO), pharmacists with a combined 35 years of experience, leveraging academic research for innovative healthcare solutions.
Headquarters: Singapore.
Company Website: https://pharlyfeplus.com/
